लोड हो रहा है...

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-designated drug, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 (PD-L1), as determin...

पूर्ण विवरण

में बचाया:

ग्रंथसूची विवरण
में प्रकाशित:	Oncologist
मुख्य लेखकों:	Sul, Joohee, Blumenthal, Gideon M., Jiang, Xiaoping, He, Kun, Keegan, Patricia, Pazdur, Richard
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	AlphaMed Press 2016
विषय:	Regulatory Issues: FDA
ऑनलाइन पहुंच:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4861368/ https://ncbi.nlm.nih.gov/pubmed/27026676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0498
टैग :	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

समान संसाधन